Polymorphism of the DL-A system

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Polymorphism of the DL-A system

Abstract

Citations

HLA C associations with acute leukaemia

Consequent intrafamilial immunization for DL-A haplotyping in canines

Histocompatibility studies in a closely bred colony of dogs. V. Mechanisms of cellular adaptation in long-term DL-A identical radiation chimeras

The influence of DL-A compatibility on the survival of hepatic allografts in unmodified mongrel dogs

The mixed leukocyte reaction in chickens. Evidence for control by the major histocompatibility complex

Histocompatibility testing in dogs. II. Leukocyte typing in relation to the mixed lymphocyte culture (MLC) reactivity

Serology and genetics of the DL-A system. I. Establishment of specificities

Raising leucocyte alloantisera in limited populations of sub-human primates

Serotyping for MLC gene products: I. Presumptive evidence that ABCIL may detect MLC factors

Polymorphism of the BoLA system

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Related Papers

In vitro immune responsiveness to vaccinea virus and HLA

Occurrence of childhood cancers among sibs and estimation of familial risks.

Random HLA-DR distribution in children with acute lymphocytic leukaemia in long-term continuous remission

Distribution of HLA genotypes in families of patients with acute leukemia. Implications for transplantation

HLA-A and HLA-B antigens in acute leukemia: A2--B12 phenotypes correlate with longer survival in acute myelogenous leukemia